The market had already been told to expect this buyback. ResMed explicitly says the ASR was contemplated in its fiscal 2027 guidance issued during the August 6, 2026 earnings call, so the filing confirms the plan rather than creating a fresh capital-return surprise. 〔0〕
The company is committing $450 million to an accelerated share repurchase. ResMed will pay Citibank on September 3, 2026 and receive an initial share delivery equal to 80% of the purchase amount divided by the September 2 closing price; the final share count will depend on the average trading price through settlement.
Funding comes from the MatrixCare sale and existing cash, not new borrowing. That makes the transaction a deployment of already-identified liquidity rather than a change in the balance-sheet strategy. 〔1〕
Net read: in line, with no incremental information advantage. The buyback is meaningful for share count and capital allocation, but because its size and timing were already contemplated in guidance, this 8-K mainly formalizes execution. Final settlement is scheduled for December 2026, though Citibank may elect to complete it earlier.
Read the original 8-K on SEC EDGAR ↗